US-based Aktis Oncology, a biotechnology company discovering and developing novel classes of targeted alpha radiopharmaceuticals to treat a broad range of solid tumours, has announced agreements with three leading medical radioisotope manufacturers NorthStar Medical Radioisotopes, Niowave and TerraPower, for preclinical, clinical and commercial supply of Actinium-225.
“Given the breadth and depth of our emerging pipeline, securing robust isotope supply across all stages of development is critical. Each of our three partners are leaders in the field of nuclear innovation with strong reputations for production, operational experience, and technical capabilities,” said Matthew Roden, President and CEO of Aktis Oncology. “We believe these foundational relationships with such high-quality suppliers will ensure timely and efficient progression of our programs and ultimately, enable patient access to potentially life-saving therapies.”
The three agreements provide Aktis with a portfolio of suppliers that utilise varied techniques to produce high quality Actinium-225, and enhance the Company’s ability to ensure just-in-time delivery of finished targeted radioconjugates to healthcare providers for administration to patients. NorthStar’s approach to Actinium-225 production is to utilise non-uranium, electron accelerator-based production methods; Niowave builds and operates superconducting electron accelerators to produce Ac-225 and other radioisotopes, whereas TerraPower uses a Thorium-229 generator. These agreements are a part of broader ongoing efforts to build and enhance Aktis’s supply access, radiomanufacturing and distribution capabilities.
